Glucocorticoids in autoimmune connective tissue diseases
Identifieur interne : 002380 ( Main/Exploration ); précédent : 002379; suivant : 002381Glucocorticoids in autoimmune connective tissue diseases
Auteurs : Victoria P. Werth [États-Unis]Source :
- Dermatologic Therapy [ 1396-0296 ] ; 2001-06.
Abstract
ABSTRACT: Glucocorticoids (GCs) are occasionally required for the cutaneous manifestations of autoimmune connective tissue diseases. In general, good therapeutic alternatives with fewer side effects than GCs are available, including anti‐inflammatory agents such as antimalarials or dapsone, or immunosuppressives such as azathioprine or methotrexate, and these can serve as GC‐sparing agents or can substitute for the use of GCs. When GC use cannot be avoided, it is important to implement a number of recommendations and improvements in dosing and prevention of side effects in order to optimize care. These include using appropriate and adequate doses of GCs initially, appropriate tapering regimens, and proper monitoring, prophylaxis, and treatment for infections, osteoporosis, avascular necrosis, hyperglycemia, hypertension, hyperlipidemia, and glaucoma.
Url:
DOI: 10.1046/j.1529-8019.2001.014002134.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000354
- to stream Istex, to step Curation: 000354
- to stream Istex, to step Checkpoint: 001206
- to stream Main, to step Merge: 002405
- to stream Main, to step Curation: 002380
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Glucocorticoids in autoimmune connective tissue diseases</title><author><name sortKey="Werth, Victoria P" sort="Werth, Victoria P" uniqKey="Werth V" first="Victoria P." last="Werth">Victoria P. Werth</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F796EC557732A4EBCA244ADBA48DBABD4E31BC03</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1046/j.1529-8019.2001.014002134.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-VN1GH6CQ-H/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000354</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000354</idno><idno type="wicri:Area/Istex/Curation">000354</idno><idno type="wicri:Area/Istex/Checkpoint">001206</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001206</idno><idno type="wicri:doubleKey">1396-0296:2001:Werth V:glucocorticoids:in:autoimmune</idno><idno type="wicri:Area/Main/Merge">002405</idno><idno type="wicri:Area/Main/Curation">002380</idno><idno type="wicri:Area/Main/Exploration">002380</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Glucocorticoids in autoimmune connective tissue diseases</title><author><name sortKey="Werth, Victoria P" sort="Werth, Victoria P" uniqKey="Werth V" first="Victoria P." last="Werth">Victoria P. Werth</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Dermatology, University of Pennsylvania, Philadelphia VA Hospital,Philadelphia</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Dermatologic Therapy</title><title level="j" type="alt">DERMATOLOGIC THERAPY</title><idno type="ISSN">1396-0296</idno><idno type="eISSN">1529-8019</idno><imprint><biblScope unit="vol">14</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="134">134</biblScope><biblScope unit="page" to="142">142</biblScope><biblScope unit="page-count">9</biblScope><publisher>Blackwell Science Inc</publisher><pubPlace>Boston, MA, USA</pubPlace><date type="published" when="2001-06">2001-06</date></imprint><idno type="ISSN">1396-0296</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1396-0296</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">ABSTRACT: Glucocorticoids (GCs) are occasionally required for the cutaneous manifestations of autoimmune connective tissue diseases. In general, good therapeutic alternatives with fewer side effects than GCs are available, including anti‐inflammatory agents such as antimalarials or dapsone, or immunosuppressives such as azathioprine or methotrexate, and these can serve as GC‐sparing agents or can substitute for the use of GCs. When GC use cannot be avoided, it is important to implement a number of recommendations and improvements in dosing and prevention of side effects in order to optimize care. These include using appropriate and adequate doses of GCs initially, appropriate tapering regimens, and proper monitoring, prophylaxis, and treatment for infections, osteoporosis, avascular necrosis, hyperglycemia, hypertension, hyperlipidemia, and glaucoma.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Pennsylvanie</li></region></list><tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Werth, Victoria P" sort="Werth, Victoria P" uniqKey="Werth V" first="Victoria P." last="Werth">Victoria P. Werth</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002380 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002380 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:F796EC557732A4EBCA244ADBA48DBABD4E31BC03
|texte= Glucocorticoids in autoimmune connective tissue diseases
}}
| This area was generated with Dilib version V0.6.33. |  |